Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Clinical evaluation of ICRF 159 as a radiosensitising agent

Journal Article · · Int. J. Radiat. Oncol., Biol. Phys.; (United States)
There is evidence that the drug ICRF 159 is a radiosensitizing agent. This clinical investigation suggests, however, that ICRF 159 is not a clinically useful radiosensitizer in that it also increases the damage done to normal tissues. Two groups of patients were studied. The first group, 12 patients who had sarcomas generally regarded as radioresistant, treated by radiotherapy with ICRF 159. They responded well to treatment, but three of them subsequently developed ususually severe post-irradiation soft tissue fibrosis. The second group, had multiple skin metastases and bilateral lung metastases from breast carcinomas. These patients were given radiotherapy with ICRF 159 to one lesion and radiotherapy alone to another similar lesion, thus each patient acted as his own control. There was a slightly better response in three of six skin tumours irradiated with ICRF 159 but more intense late skin changes in four of them. The tumor response in the patient with bilateral lung metastases was similar on each side but the lung which was irradiated with ICRF 159 subsequently developed a severe radiation pneumonitis.
Research Organization:
St. Thomas' Hospital, London
OSTI ID:
5043549
Journal Information:
Int. J. Radiat. Oncol., Biol. Phys.; (United States), Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Vol. 4:1/2; ISSN IOBPD
Country of Publication:
United States
Language:
English